Isoliquiritigenin Inhibits the Growth of Colorectal Cancer Cells through the ESR2/PI3K/AKT Signalling Pathway

Isoliquiritigenin Inhibits the Growth of Colorectal Cancer Cells through the ESR2/PI3K/AKT Signalling Pathway

Colorectal cancer (CRC) is one of the most common malignancies. Isoliquiritigenin (ISL), a flavonoid phytoestrogen, has shown anti-tumour activities against various cancers. However, its anti-CRC mechanism has not been clarified. In this study, the potential molecular mechanism of ISL against CRC wa...

Full description

Bibliographic Details
Main Authors: Fenglin Luo, Yimeng Tang, Lin Zheng, Ying Yang, Haoyue Gao, Shiya Tian, Hongyu Chen, Chenxi Tang, Shanshan Tang, Qiong Man, Yiying Wu
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Pharmaceuticals
Subjects:
colorectal cancer
Isoliquiritigenin
network pharmacology
ESR2
PI3K/AKT pathway
Online Access:https://www.mdpi.com/1424-8247/17/1/43

Internet

https://www.mdpi.com/1424-8247/17/1/43

Similar Items